Home » Newsletters » BioWorld Asia

BioWorld Asia

Sep. 13, 2000

View Archived Issues

PowderJect To Pay US$79.2M For Celltech's Vaccine Arm

Cureon To Develop Therapeutic Applications Of LNA Platform

Cell Therapy More Promising After Stem Cell Breakthrough

Peptor Diabetes Drug Looks Promising At Phase II Interim

European Parliament Condemns British Decision To Allow Cloning

Antisoma Harnesses Cyanide, Antibodies For Cancer Therapy

Medarex To Create Antibodies For OGS Proteomics Targets

IsoTis Gearing Up For Trials, October Stock Market Float

ExonHit Raises US$12M, Prepares For IPO In 2001

Biotie Targets Inflammation Protein With Dual Activity

Amrad Advances Clinical Slate, Including HBV, Pain Therapies

Other News To Note

Bionomics Seeking Partners For Cancer, Epilepsy Genes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...